PSNL's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.51 -- higher than merely 6.3% of US-listed equities with positive expected earnings growth.
PSNL's went public 1.44 years ago, making it older than just 2.08% of listed US stocks we're tracking.
The volatility of Personalis Inc's share price is greater than that of 91.83% US stocks with at least 200 days of trading history.
If you're looking for stocks that are quantitatively similar to Personalis Inc, a group of peers worth examining would be EPZM, JG, CERS, PACB, and FIT.
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
Investment thesis With the recent launch of Liquid Biopsy, China expansion, machine learning platform later in the year and a slight pivot to attempting to sell population sequencing to more countries, Personalis has become an even more enticing opportunity. Developments since IPO On June 7, 2019 I published an article...
Birgir Magnusson on Seeking Alpha | August 31, 2020
Personalis (PSNL) has priced its public offering of 6,578,947 common stock at $19/share, for expected gross proceeds of $125M. Underwriters' over-allotment is an additional 986,842 shares of common stock from a selling stockholder.The company will not receive any proceeds from any sale of shares by the selling stockholder."PSNL is seeing...